ReviewNutrients2022
Significance of Gut Microbiota and Short-Chain Fatty Acids in Heart Failure.
Review in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Bibliometric analysis of the trends in research on the link between gut microbiota and pancreatic cancer.Frontiers in cellular and infection microbiology · 2026Pooled it
- Short-Chain Fatty Acids in Heart Failure with Preserved Ejection Fraction: Pathophysiological Roles and Therapeutic Potential.International journal of molecular sciences · 2026Review
- Micro-nanoplastics in Cardiovascular Disease: A Critical Update from Environmental Exposure to Clinical Implications.Cardiovascular toxicology · 2026Review
- Gut Microbiota as an Innovative Therapeutic Target in Cardiovascular Diseases from a Metabolic and Inflammatory Perspective.Biomedicines · 2026Review
- Metabolomic analysis reveals the role of gut microbiota metabolic disorders in heart failure due to congenital heart disease.Scientific reports · 2026Article
- Probiotic Lactic Acid Bacteria-Fermented Beverages from Bambara Groundnut and Cowpea Sprouts Modulate Gut Microbiota and Short-Chain Fatty Acids.Foods (Basel, Switzerland) · 2026Article
- The gut-heart axis in heart failure: from bidirectional pathophysiological mechanisms to integrative therapeutic strategies.Frontiers in microbiology · 2026Review
- The role of the gut microbiota and metabolites in heart failure and possible implications for treatment.Heart failure reviews · 2025Review
- How the Microbiome Drives Cardiovascular Disease.The Surgical clinics of North America · 2025Review
- Immunometabolism in heart failure.Nature reviews. Cardiology · 2025Review
- Serum metabolic profiling in rheumatic heart disease and degenerative aortic stenosis.Scientific reports · 2025Article
- Dissecting the role of gut microbiota heterogeneity in the onset of chronic lung diseases.AMB Express · 2025Article
- Article
- Oral 7,8-Dihydroxyflavone Protects Retinal Ganglion Cells by Modulating the Gut-Retina Axis and Inhibiting Ferroptosis via the Indoleacrylic Acid-AhR-ALDH1A3-FSP1 Pathway.CNS neuroscience & therapeutics · 2025Article
- Lactate orchestrates metabolic hemodynamic adaptations through a unique combination of venocontraction, artery relaxation, and positive inotropy.Acta physiologica (Oxford, England) · 2025Article
- Antibiotic-induced gut dysbiosis: unraveling the gut-heart axis and its impact on cardiovascular health.Molecular biology reports · 2025Review
- Association of Circulating Phenylacetylglutamine With Multi-Vessel Coronary Disease Severity and Outcomes in ST-Segment-Elevation Myocardial Infarction.Journal of the American Heart Association · 2025Article
- Short-Chain Fatty Acids and Their Metabolic Interactions in Heart Failure.Biomedicines · 2025Review
- Progress on the mechanism of intestinal microbiota against colorectal cancer.Frontiers in cellular and infection microbiology · 2025Review
- Cardiac energy metabolic disorder and gut microbiota imbalance: a study on the therapeutic potential of Shenfu Injection in rats with heart failure.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Heart failure (HF), as the terminal stage of various heart diseases, seriously threatens an individual's life, health, and quality of life. Emerging evidence has shown that the gut microbiota comprises an important component of human physiology and metabolic homeostasis, and can directly or indirectly affect the metabolic health of the host through metabolites. Upon in-depth study of intestinal microecology, the "gut-heart axis" appears to provide a novel direction for HF research. Thus, this review primarily focuses on the relationship between the gut microbiota and its major metabolites-i.e., short-chain fatty acids (SCFAs)-and HF. It explores the mechanisms underlying HF and its effective treatment by targeting SCFAs to optimize current HF treatment and thus improve the quality of patients' lives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.